Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773568 | 0.89 | L3MBTL1 (0.41) | MAPTMEN1KMT2AWDR5 | |
| SCHEMBL6770466 | 0.89 | MAPT (0.45) | RAB9ANPC1SMN1; SMN2CA2MAPT | |
| SCHEMBL6777480 | 0.86 | XDH (0.43) | RAB9ANPC1DHODHMAPTMEN1 | |
| SCHEMBL7359461 | 0.84 | DHODH (0.44) | ABCB1RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL7400116 | 0.84 | DHODH (0.47) | ABCB1RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL6768158 | 0.83 | SMN1; SMN2 (0.45) | ABCB1RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL6773137 | 0.83 | CREBBP (0.47) | RAB9ANPC1SMN1; SMN2GAAMEN1 | |
| SCHEMBL6772512 | 0.83 | LMNA (0.53) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6778783 | 0.82 | ABCB1 (0.42) | ABCB1RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL6773412 | 0.81 | BRD4 (0.52) | RAB9ANPC1SMN1; SMN2GAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | claimed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | claimed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | claimed |
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | disclosed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | disclosed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | GABRA1, GABRA4, GABRA2 | ABCB1 1022/4885RAB9A 1157/4885NPC1 1043/4885 |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | CNR1, HTR1A, GABRA6 | ABCB1 959/4885RAB9A 2080/4885NPC1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.